
Opinion|Videos|July 30, 2024
Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC
Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5














